Don't Forget To
Rate This Article

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Telemedicine Co. Surges on Revenue News

Share on Stocktwits


As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.

Shares of telemedicine company Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) went up nearly 20% this week on news that its revenue increased 485% to CA$8.6 million from the fiscal year 2021 to the fiscal year 2022.

Expert Clive Maund wrote on Tuesday, saying it was a “good time to buy.”



Its share price went up from CA$0.52 to CA$0.62 the day the news was released on Wednesday. The day before, technical analyst Clive Maund wrote that the stock was “believed to have been in a basing process since last May.”

“It attempted to break higher on increased volume about a week ago, but with its 200-day moving average still dropping toward the price overhead, it was not quite ready,” he wrote on Tuesday, saying it was a “good time to buy.”

Jefferson Research also raised its rating of the stock from Sell to Hold, saying its earnings quality in the third quarter went from “strong” to “strongest,” and its cash flow quality improved from “weak” to “strong.”

“Cash flow is considered by many investors to be the ultimate measure of company performance and more reliable than reported earnings,” Jefferson wrote.

Huge changes because of the COVID-19 pandemic have contributed to the increasing acceptance of home-based services, Reliq Chief Executive Officer Lisa Crossley told Streetwise Reports.

The company said gross profits increased YOY by more than 515% to CA$5.3 million, and the gross margin for the year was 62%.

“COVID helped with getting clinicians who otherwise weren't particularly comfortable with the concept of virtual care and forced them to be comfortable,” Crossley said. “That's definitely helped drive adoption for us.”

The company said gross profits increased YOY by more than 515% to CA$5.3 million, and the gross margin for the year was 62%.

Revenue for Reliq’s software and service sales increased more than 1,940% to CA$2.7 million for the fiscal year 2022, which ended June 30, compared to more than CA$134,000 for the fiscal year 2021.

The company said gross profits increased YOY by more than 515% to CA$5.3 million, and the gross margin for the year was 62%.

The Catalyst

Internet-enabled health care is becoming more accepted in the wake of the pandemic. Government and private insurance plans have expanded their coverage for the services, allowing more doctors to look at remote solutions like Reliq’s remote patient monitoring and virtual care platform.

Reliq expects to have as many as 200,000 patients on its platform by the middle of 2023.

“We have a certain number of clients and patients (that have already) announced and committed” to the platform, Crossley said. “But we're also starting to really pick up in terms of the size of contracts that we're signing and the size of clients that we're working with.”

Reliq recently signed new contracts, including expanding one with a network of skilled nursing facilities in Florida to add as many as 60,000 new patients per year onto the platform, iUGO. Each patient is expected to generate US$65 per month at a 75% gross margin.

Word of Mouth

Crossley said the company is expecting rapid growth the more contracts it signs with such facilities.

“We’ve gotten to the point where word of mouth is really driving a lot of our business, but not just with individual physician practices and home health agencies, but with these much larger networks,” she said.

Skilled nursing facilities are a largely untapped market for the company. Reliq said there are over 15,000 of them in the United States and more than 1.5 million Medicare patients received care from such networks in 2021.

The average practice can generate new revenue of more than US$400 per patient per month with the platform while paying US$40 to US$100 per patient per month to subscribe to iUGO.

The company also does the pre-screening and pre-authorizations with Medicare and Medicaid and electronic submissions for payment.

Diseases the company aims to manage at home include chronic obstructive pulmonary disease (COPD), congestive heart failure, diabetes, hypertension, and others. Patients get audible reminders to step on a scale, take their blood pressure, or prick their fingers for glucose monitoring. The information is automatically uploaded to the cloud.

Ownership and Share Structure

Top shareholders include Crossley, who owns 1.56% or 3 million shares; Penserra Capital Management LLC, which owns 0.23% or 0.43 million shares; and Eugene Beukman, who owns 0.12% or 0.23 million shares, according to Reuters.

The company has 191.5 million shares outstanding, with 188 million of them free-floating. It has a market cap of CA$128 million and trades in a 52-week range of CA$1.33 and CA$0.36.

Want to be the first to know about interesting Life Sciences Tools & Diagnostics, Technology and Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. Subscribe

1) Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Reliq Health Technologies Inc. Click here for important disclosures about sponsor fees. 

3) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

4) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Technologies Inc., a company mentioned in this article.

5) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Life Sciences Tools & Diagnostics, Technology and Healthcare Services investment ideas?
Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe